Analysis of 14 LRRK2 mutations in Parkinson's plus syndromes and late-onset Parkinson's disease

E. K. Tan, Lisa Skipper, Eva Chua, Meng Cheong Wong, Ratnagopal Pavanni, Carine Bonnard, Prasanna Kolatkar, Jian Jun Liu

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

The pleomorphic pathology of postmortem LRRK2-positive patients and the frequent association with late-onset Parkinson's disease (LOPD) symptoms suggest that LRRK2 mutations may play a role in Parkinson's Plus disorders and LOPD. Published studies primarily focus on the common G2019S mutation. Analysis of a spectrum of LRRK2 mutations in Parkinson's Plus disorders has yet to be reported. We investigated 14 leucine-rich repeat kinase 2 (LRRK2) mutations in a cohort of Parkinson's Plus disorders and LOPD. A total of 458 patients with progressive supranuclear palsy (PSP), multiple system atrophy (MSA), corticobasal ganglionic degeneration (CBGD), atypical Parkinsonism (AP), and LOPD were screened for 14 mutations that span exons 19 to 41 of the LRRK2 gene. Among the LOPD cases, 1 patient was found to harbor the R1441C mutation. He presented with typical features of PD at age of 58 years old and responded well to levodopa. We did not detect any of the 14 mutations in PSP, MSA, CBGD, and AP patients. We highlight the first case of LRRK2 R1441C mutation in late onset sporadic PD of non-European ancestry. Furthermore, extensive mutational screen found LRRK2 mutations to be rare among patients who presented with PSP, MSA, CBGD, and AP.

Original languageEnglish
Pages (from-to)997-1001
Number of pages5
JournalMovement Disorders
Volume21
Issue number7
DOIs
Publication statusPublished - 1 Jul 2006
Externally publishedYes

Fingerprint

Leucine
Parkinson Disease
Phosphotransferases
Mutation
Progressive Supranuclear Palsy
Multiple System Atrophy
Parkinsonian Disorders
Late Onset Disorders
Levodopa
Exons
Spectrum Analysis
Pathology
Genes

Keywords

  • LRRK2
  • Mutation
  • Parkinson's disease
  • Parkinson's Plus syndrome

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Tan, E. K., Skipper, L., Chua, E., Wong, M. C., Pavanni, R., Bonnard, C., ... Liu, J. J. (2006). Analysis of 14 LRRK2 mutations in Parkinson's plus syndromes and late-onset Parkinson's disease. Movement Disorders, 21(7), 997-1001. https://doi.org/10.1002/mds.20875

Analysis of 14 LRRK2 mutations in Parkinson's plus syndromes and late-onset Parkinson's disease. / Tan, E. K.; Skipper, Lisa; Chua, Eva; Wong, Meng Cheong; Pavanni, Ratnagopal; Bonnard, Carine; Kolatkar, Prasanna; Liu, Jian Jun.

In: Movement Disorders, Vol. 21, No. 7, 01.07.2006, p. 997-1001.

Research output: Contribution to journalArticle

Tan, EK, Skipper, L, Chua, E, Wong, MC, Pavanni, R, Bonnard, C, Kolatkar, P & Liu, JJ 2006, 'Analysis of 14 LRRK2 mutations in Parkinson's plus syndromes and late-onset Parkinson's disease', Movement Disorders, vol. 21, no. 7, pp. 997-1001. https://doi.org/10.1002/mds.20875
Tan, E. K. ; Skipper, Lisa ; Chua, Eva ; Wong, Meng Cheong ; Pavanni, Ratnagopal ; Bonnard, Carine ; Kolatkar, Prasanna ; Liu, Jian Jun. / Analysis of 14 LRRK2 mutations in Parkinson's plus syndromes and late-onset Parkinson's disease. In: Movement Disorders. 2006 ; Vol. 21, No. 7. pp. 997-1001.
@article{ab7e710d67434c09972cc953315194f2,
title = "Analysis of 14 LRRK2 mutations in Parkinson's plus syndromes and late-onset Parkinson's disease",
abstract = "The pleomorphic pathology of postmortem LRRK2-positive patients and the frequent association with late-onset Parkinson's disease (LOPD) symptoms suggest that LRRK2 mutations may play a role in Parkinson's Plus disorders and LOPD. Published studies primarily focus on the common G2019S mutation. Analysis of a spectrum of LRRK2 mutations in Parkinson's Plus disorders has yet to be reported. We investigated 14 leucine-rich repeat kinase 2 (LRRK2) mutations in a cohort of Parkinson's Plus disorders and LOPD. A total of 458 patients with progressive supranuclear palsy (PSP), multiple system atrophy (MSA), corticobasal ganglionic degeneration (CBGD), atypical Parkinsonism (AP), and LOPD were screened for 14 mutations that span exons 19 to 41 of the LRRK2 gene. Among the LOPD cases, 1 patient was found to harbor the R1441C mutation. He presented with typical features of PD at age of 58 years old and responded well to levodopa. We did not detect any of the 14 mutations in PSP, MSA, CBGD, and AP patients. We highlight the first case of LRRK2 R1441C mutation in late onset sporadic PD of non-European ancestry. Furthermore, extensive mutational screen found LRRK2 mutations to be rare among patients who presented with PSP, MSA, CBGD, and AP.",
keywords = "LRRK2, Mutation, Parkinson's disease, Parkinson's Plus syndrome",
author = "Tan, {E. K.} and Lisa Skipper and Eva Chua and Wong, {Meng Cheong} and Ratnagopal Pavanni and Carine Bonnard and Prasanna Kolatkar and Liu, {Jian Jun}",
year = "2006",
month = "7",
day = "1",
doi = "10.1002/mds.20875",
language = "English",
volume = "21",
pages = "997--1001",
journal = "Movement Disorders",
issn = "0885-3185",
publisher = "John Wiley and Sons Inc.",
number = "7",

}

TY - JOUR

T1 - Analysis of 14 LRRK2 mutations in Parkinson's plus syndromes and late-onset Parkinson's disease

AU - Tan, E. K.

AU - Skipper, Lisa

AU - Chua, Eva

AU - Wong, Meng Cheong

AU - Pavanni, Ratnagopal

AU - Bonnard, Carine

AU - Kolatkar, Prasanna

AU - Liu, Jian Jun

PY - 2006/7/1

Y1 - 2006/7/1

N2 - The pleomorphic pathology of postmortem LRRK2-positive patients and the frequent association with late-onset Parkinson's disease (LOPD) symptoms suggest that LRRK2 mutations may play a role in Parkinson's Plus disorders and LOPD. Published studies primarily focus on the common G2019S mutation. Analysis of a spectrum of LRRK2 mutations in Parkinson's Plus disorders has yet to be reported. We investigated 14 leucine-rich repeat kinase 2 (LRRK2) mutations in a cohort of Parkinson's Plus disorders and LOPD. A total of 458 patients with progressive supranuclear palsy (PSP), multiple system atrophy (MSA), corticobasal ganglionic degeneration (CBGD), atypical Parkinsonism (AP), and LOPD were screened for 14 mutations that span exons 19 to 41 of the LRRK2 gene. Among the LOPD cases, 1 patient was found to harbor the R1441C mutation. He presented with typical features of PD at age of 58 years old and responded well to levodopa. We did not detect any of the 14 mutations in PSP, MSA, CBGD, and AP patients. We highlight the first case of LRRK2 R1441C mutation in late onset sporadic PD of non-European ancestry. Furthermore, extensive mutational screen found LRRK2 mutations to be rare among patients who presented with PSP, MSA, CBGD, and AP.

AB - The pleomorphic pathology of postmortem LRRK2-positive patients and the frequent association with late-onset Parkinson's disease (LOPD) symptoms suggest that LRRK2 mutations may play a role in Parkinson's Plus disorders and LOPD. Published studies primarily focus on the common G2019S mutation. Analysis of a spectrum of LRRK2 mutations in Parkinson's Plus disorders has yet to be reported. We investigated 14 leucine-rich repeat kinase 2 (LRRK2) mutations in a cohort of Parkinson's Plus disorders and LOPD. A total of 458 patients with progressive supranuclear palsy (PSP), multiple system atrophy (MSA), corticobasal ganglionic degeneration (CBGD), atypical Parkinsonism (AP), and LOPD were screened for 14 mutations that span exons 19 to 41 of the LRRK2 gene. Among the LOPD cases, 1 patient was found to harbor the R1441C mutation. He presented with typical features of PD at age of 58 years old and responded well to levodopa. We did not detect any of the 14 mutations in PSP, MSA, CBGD, and AP patients. We highlight the first case of LRRK2 R1441C mutation in late onset sporadic PD of non-European ancestry. Furthermore, extensive mutational screen found LRRK2 mutations to be rare among patients who presented with PSP, MSA, CBGD, and AP.

KW - LRRK2

KW - Mutation

KW - Parkinson's disease

KW - Parkinson's Plus syndrome

UR - http://www.scopus.com/inward/record.url?scp=33746870719&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746870719&partnerID=8YFLogxK

U2 - 10.1002/mds.20875

DO - 10.1002/mds.20875

M3 - Article

VL - 21

SP - 997

EP - 1001

JO - Movement Disorders

JF - Movement Disorders

SN - 0885-3185

IS - 7

ER -